Dr K.D. is an Associate Professor of Respiratory Medicine and his research interests include mycobacterial host immunity, development of field-friendly diagnostics and mycobacterial drug resistance. Dr S.K.S. is an Associate Professor of Public and Global Public Health. His laboratory-based research focuses on human antimycobacterial immunity and its environmental confounders. Dr B.Z. is an Associate Professor of Pathogenic Biology with primary research interests in tuberculosis subunit vaccine and pathogenesis. Dr R.V.Z.S. is a pulmonologist and research fellow with research interests in tobacco smoking and tuberculosis immunity. Dr Y.Z. is a Professor of Microbiology and Immunology and his research interests include tuberculosis pathogenesis, drug resistance, persistence and host responses to mycobacterial infections.
The immunology of tuberculosis: From bench to bedside
Article first published online: 29 MAR 2010
© 2010 The Authors; Journal compilation © 2010 Asian Pacific Society of Respirology
Volume 15, Issue 3, pages 433–450, April 2010
How to Cite
DHEDA, K., SCHWANDER, S. K., ZHU, B., Van ZYL-SMIT, R. N. and ZHANG, Y. (2010), The immunology of tuberculosis: From bench to bedside. Respirology, 15: 433–450. doi: 10.1111/j.1440-1843.2010.01739.x
SERIES EDITORS: WING WAI YEW, GIOVANNI B. MIGLIORI AND CHRISTOPH LANGE
- Issue published online: 29 MAR 2010
- Article first published online: 29 MAR 2010
- Received 18 November 2009; invited to revise 24 November 2009, revised 1 December 2009; accepted 8 December 2009.
Tuberculosis (TB) is an international public health priority and kills almost two million people annually. TB is out of control in Africa due to increasing poverty and HIV coinfection, and drug-resistant TB threatens to destabilize TB control efforts in several regions of the world. Existing diagnostic tools and therapeutic interventions for TB are suboptimal. Thus, new vaccines, immunotherapeutic interventions and diagnostic tools are urgently required to facilitate TB control efforts. An improved understanding of the immunopathogenesis of TB can facilitate the identification of correlates of immune protection, the design of effective vaccines, the rational selection of immunotherapeutic agents, the evaluation of new drug candidates, and drive the development of new immunodiagnostic tools. Here we review the immunology of TB with a focus on aspects that are clinically and therapeutically relevant. An immunologically orientated approach to tackling TB can only succeed with concurrent efforts to alleviate poverty and reduce the global burden of HIV.